Interferons have long occupied a privileged place in immunology. These pro-inflammatory signaling proteins act as molecular alarms, rushing to the site of a nascent cancer and recruiting specialized immune cells such as T cells and B cells to seek out and destroy malignant tissue. This early interferon response is widely regarded as a critical and powerful component of the body’s natural cancer surveillance. Yet clinicians and researchers have repeatedly observed a troubling pattern: in established tumors, interferon signaling that persists too long often correlates with worse outcomes, immune evasion, and resistance to checkpoint blockade therapies such as anti-PD1. Why a protein that begins as an anti-cancer warrior becomes a tumor’s accomplice has remained one of the field’s most stubborn open questions.

The Salk team, led by senior author Gerald Shadel, professor and holder of the Audrey Geisel Chair in Biomedical Science, approached the mystery from an unusual angle—the mitochondria. Shadel’s laboratory has spent years investigating how these cellular powerhouses communicate with the immune system, most notably through their discovery that mitochondria can provoke interferon responses by releasing their genetic material, mitochondrial DNA, into the rest of the cell, where it is perceived as a foreign invader. For the new study, the researchers deliberately inverted this question. Rather than asking how mitochondria shape interferon signaling, they asked how sustained interferon exposure reshapes mitochondrial function—and whether that remodeling could hold the key to the paradox of pro-tumor interferon activity.

To find out, the team exposed melanoma cells in the laboratory to type I or type II interferons for either brief, acute periods or extended, chronic periods. The differences were dramatic. Acute interferon exposure left the mitochondria largely unscathed, but chronic exposure produced measurable deterioration in the organelles’ energetic function. When the researchers then transferred these chronically exposed melanoma cells into a mouse model, they made an unexpected and consequential observation: chronic interferon II exposure did not slow tumor growth—it enhanced it. The finding provided a clean experimental demonstration that the duration of interferon signaling, not merely its presence, determines whether it helps or harms the host in the fight against cancer.

Digging into the cellular machinery behind this switch, the researchers uncovered a previously unknown pathway that begins deep inside the mitochondria. Chronic type II interferon exposure causes mitochondrial RNA, or mtRNA, to escape the confines of the organelle and leak into the main body of the cell. Sensing this misplaced genetic material, the cell’s innate immune surveillance systems interpret it as evidence of viral invasion and respond by producing type I interferon—a second, distinct interferon family. Type I and type II interferons then act in concert to drive up the levels of an enzyme called cyclooxygenase 2, which in turn increases the synthesis of a bioactive lipid known as prostaglandin E2. This lipid messenger, long associated with inflammation and immunosuppression in tumors, effectively flips the tumor microenvironment from a state of immune attack to one of immune tolerance.

The identification of prostaglandin E2 as the linchpin of this pathway immediately suggested a therapeutic test. If this lipid signal was the agent responsible for damping down the immune response, the researchers reasoned, then preventing melanoma cells from manufacturing it might restore the immune system’s ability to see and attack the cancer. The stakes of this question extend well beyond basic biology. Anti-PD1 immunotherapies—among the most widely used cancer treatments in the world today—work by blocking a signal that cancer cells deploy to keep immune cells at bay. But tumors frequently deploy additional, independent immunosuppressive pathways, allowing them to continue growing even in patients receiving anti-PD1 treatment. Understanding and disabling those alternative escape routes is one of the most urgent challenges in modern oncology.

“Chronic interferon exposure is a major factor in immunotherapy resistance,” said Melissa Johnson, a graduate student researcher in Shadel’s laboratory and first author of the study. “We wondered whether cancer cells that have become resistant to anti-PD1 therapy were upregulating the immunosuppressive mitochondria-centered pathway we identified, and whether that pathway is a viable target for combating immunotherapy resistance.” The team’s experimental results answered that question with unusual force. When the researchers blocked prostaglandin E2 synthesis in mouse melanoma cells, the immune system’s capacity to recognize and destroy the cancer was restored. More remarkably, blocking the lipid signal reversed resistance to anti-PD1 therapy itself: in nine out of ten mice, tumors that had previously shrugged off immunotherapy regressed completely and did not return.

The completeness and durability of those responses set the findings apart from typical incremental advances in tumor immunology. Rather than merely slowing tumor growth, eliminating the prostaglandin E2 signal appeared to reawaken a sustained, effective anti-tumor immune attack—suggesting that the mitochondria-to-prostaglandin pathway is not simply one suppressive mechanism among many, but a genuine molecular switch governing whether the tumor microenvironment invites or repels immune destruction. In the melanoma model, flipping that switch off was sufficient to transform an immunologically “cold,” therapy-resistant tumor back into one the immune system could eradicate.

The implications for future cancer treatment are considerable. The study points to a potential strategy for sustaining the immune system’s assault on tumors by intervening in the mitochondrial signaling axis rather than, or in addition to, checkpoint blockade. Because the pathway is cell-autonomous—operating within the tumor cells themselves—it offers a target that may complement existing immunotherapies and provide an option for patients whose cancers have exhausted the benefits of anti-PD1 agents. While the work remains at the preclinical stage in mouse models, the researchers emphasize that the pathway’s components, from mtRNA release to cyclooxygenase 2 activity to prostaglandin E2 production, represent a series of druggable nodes that could each be targeted therapeutically. Existing drugs that inhibit cyclooxygenase enzymes, for example, raise the possibility of repurposing well-characterized compounds to disrupt the pathway at its enzymatic core.

Beyond its immediate translational promise, the work carries a broader conceptual message for cancer biology: mitochondrial signaling cannot be treated as a background housekeeping function when modeling how tumors interact with the immune system. Shadel’s team demonstrated that a signaling molecule long classified purely as an immune modulator exerts direct, physical effects on mitochondrial integrity within cancer cells, and that those effects feed forward into an inflammatory lipid axis with decisive immunological consequences. The finding enriches the field’s understanding of how the immune system attacks cancer cells but can also be stymied by other factors in the tumor environment, and it makes a compelling case for integrating mitochondrial signaling functions into the design and interpretation of cancer studies.

For a question that has puzzled the field for decades—why the immune system sometimes helps tumors grow—the Salk team has delivered not just an explanation but a roadmap. Chronic interferon II drives mitochondrial RNA out of its organelle home, ignites a type I interferon response inside the tumor cell itself, amplifies cyclooxygenase 2, floods the microenvironment with prostaglandin E2, and thereby blindfolds the immune system at the very moment it should be striking. Cut the pathway at its lipid endpoint, and the blindfold falls away. The research was funded by the National Institutes of Health alongside private philanthropic support from the Glenn Foundation for Medical Research, the Cancer Research Institute, the NOMIS Foundation, and others, and the team included contributors spanning immunology, metabolism, and epigenetics—an interdisciplinary breadth that mirrors the pathway’s own reach across cellular compartments. As immunotherapy resistance continues to challenge clinicians worldwide, this mitochondria-centered mechanism offers a durable answer to a longstanding mystery and, potentially, a powerful new lever to pull in the clinic.

Cuproptosis, a copper-dependent form of cell demise, represents a unique mode of regulated cell death distinctly different from apoptosis or necroptosis. It is triggered by intracellular accumulation of copper ions, which disrupt mitochondrial respiration and lead to proteotoxic stress and cell death. Although the copper ion’s cytotoxic properties have been acknowledged for decades, the revelation of cuproptosis as an active biological process sensitive to copper overload has opened new horizons for therapeutic exploitation. Certain malignancies, it appears, exhibit heightened vulnerability to this form of cell death, suggesting a promising target for future anticancer modalities.

The study, led by Dr. Boyi Gan, professor in Experimental Radiation Oncology at MD Anderson, elegantly demonstrates that when cancer cells undergo cuproptosis, they do not simply die quietly; rather, they emit signals that robustly activate the immune system. These signals recruit and stimulate CD8-positive cytotoxic T cells, immune effectors pivotal in targeting and eradicating malignant cells. Through meticulously designed preclinical models, Gan and colleagues revealed a dynamic crosstalk whereby immune cells enhance the susceptibility of cancer cells to cuproptosis, whilst the resultant cell death further amplifies antitumor immunity, establishing a positive feedback mechanism that could be leveraged therapeutically.

Importantly, this research delved into the persistent challenge of immunotherapy resistance. While immune checkpoint inhibitors have transformed the landscape of oncology, a significant subset of patients either fails to respond from the outset or relapses due to acquired resistance mechanisms. Gan’s team discovered that administering agents that induce cuproptosis alongside anti-PD-L1 immunotherapy markedly improved tumor control even in models resistant to checkpoint blockade alone. This combinatorial approach effectively synergizes cellular and immune-mediated tumor suppression, suggesting a powerful paradigm shift in treatment strategies.

At the molecular level, the study identified the gene FDX1 as a crucial determinant in mediating cancer cell sensitivity to cuproptosis. FDX1 encodes ferredoxin 1, a mitochondrial reductase that influences intracellular copper handling and redox balance. Elevated FDX1 expression correlated with increased responsiveness to the cuproptosis-triggering regimen, indicating that it may serve as an important biomarker to predict patient benefit from such therapies. This insight opens avenues for personalized medicine, enabling oncologists to tailor interventions based on tumor biology.

The implications of this discovery extend beyond therapeutic development. Understanding the interplay between metal ion homeostasis and immune function unravels previously uncharted dimensions of tumor immunobiology. The concept of employing metal ion dysregulation to amplify immune-mediated tumor clearance challenges traditional paradigms and presents numerous opportunities for designing next-generation cancer therapeutics that integrate biochemical vulnerabilities with immune modulation.

Given that several cuproptosis-inducing compounds investigated in this study already have established clinical safety profiles, translating these findings into clinical trials may proceed with relative expediency. Such trials could rapidly assess the efficacy and safety of combining copper-dependent cell death inducers with immune checkpoint blockade in patients with refractory or resistant cancers, potentially expanding the currently limited therapeutic arsenal.

Moreover, elucidation of the mechanisms underlying cuproptosis-induced immune activation might inspire the identification of novel immune stimulatory molecules or pathways that can be harnessed pharmacologically. These discoveries could broaden the translational scope by refining immunotherapeutic regimens or overcoming resistance in other treatment-resistant malignancies.

The two-way interaction revealed between CD8+ T cells and cuproptotic death not only deepens our grasp of tumor-immune interface biology but also emphasizes the complexity of the tumor microenvironment. This interplay highlights the importance of considering cellular death modalities not merely as endpoints but as active participants in shaping immune responses and therapeutic outcomes.

In conclusion, the study presents a compelling argument for the integration of cuproptosis induction with immunotherapy as a promising strategy to overcome resistance, a formidable challenge that has long constrained the success of immune-based cancer treatments. As cancer continues to evolve mechanisms of evading immune surveillance, innovative approaches such as these are imperative to outmaneuver the disease’s adaptability.

Ongoing research is expected to refine the molecular markers that predict response, optimize dosing regimens, and evaluate long-term efficacy and safety across diverse cancer types. This advancement represents a critical step toward developing resilient and durable treatment strategies, providing renewed hope for patients with difficult-to-treat tumors.

Dr. Boyi Gan and his team’s pioneering work stands at the nexus of biochemistry, immunology, and oncology, illustrating how interdisciplinary efforts can yield transformative insights. By bridging fundamental discoveries with clinical potential, this study paves the way for a new era in cancer therapy where the immune system is empowered by precisely targeted cell death mechanisms.

This transformative research was supported by the National Institutes of Health, the Cancer Prevention & Research Institute of Texas, and institutional grants from UT MD Anderson, underscoring the vital role of collaborative funding in propelling innovation in cancer science.

Subject of Research: Animals

Article Title: Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance

News Publication Date: 22-Jun-2026

Web References: https://doi.org/10.1016/j.cell.2026.05.036

Image Credits: The University of Texas MD Anderson Cancer Center

Keywords: Cuproptosis, Immunotherapy resistance, Copper-induced cell death, CD8-positive T cells, FDX1 gene, Cancer, Immune activation, Checkpoint inhibitors, Tumor microenvironment, Molecular biomarkers, Experimental Radiation Oncology

Ferroptosis has emerged as a captivating mode of cell death owing to its reliance on iron-mediated lipid peroxidation and reactive oxygen species (ROS), setting it apart mechanistically from apoptosis or necrosis. Yet, the crosstalk between autophagy—especially LC3B-mediated autophagic flux—and ferroptosis in bladder cancer remains inadequately explored. This study leverages a comprehensive multimodal approach integrating cellular assays, murine xenograft models, and transcriptomics, including single-cell RNA sequencing, to unravel the molecular underpinnings by which JS-K exploits this axis to suppress tumor progression.

Cell culture experiments employing human bladder cancer lines T24 and UM-UC-3 unveiled classical hallmarks of ferroptosis upon JS-K administration. These included distinctive mitochondrial shrinkage observed via electron microscopy, excessive lipid peroxidation evidenced by malondialdehyde accumulation, an overwhelming surge in intracellular ROS, and iron overload. Concomitantly, pivotal ferroptosis safeguard proteins glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11 or xCT) were markedly downregulated, signifying a collapse of cellular antioxidative defenses.

Crucially, impairment or genetic silencing of LC3B—a core autophagy protein—dampened JS-K’s ability to induce iron build-up, oxidative damage, and consequent cell death. This elegant finding positions autophagy upstream as a facilitator rather than merely a bystander of ferroptosis in this context. The data imply that autophagic processes may selectively degrade ferritin or other iron storage complexes, incrementally raising free iron levels that catalyze lipid peroxidation and ferroptotic demise.

Extending these observations in vivo, JS-K administered to immunodeficient BALB/c nude mice bearing human bladder cancer xenografts produced significant tumor growth inhibition. Importantly, mice harboring tumors with silenced LC3B expression exhibited an attenuated therapeutic response, corroborating the mechanistic necessity of autophagy for optimal ferroptosis induction and antitumor efficacy. Histopathological assessment further confirmed altered protein expression patterns consistent with ferroptotic cell death pathways.

Interrogation of bulk and single-cell RNA-sequencing datasets from treated tumor tissues illuminated co-expression networks linking LC3B with ferroptosis-associated genes including CISD1 and nuclear receptor coactivator 4 (NCOA4). Among these, CISD1 emerged as a prognostically relevant biomarker, inversely correlating with clinical outcomes and highlighting its potential utility in stratifying patients for autophagy–ferroptosis-targeted therapies.

At the cellular level, JS-K’s release of nitric oxide initiates mitochondrial impairment by disrupting electron transport chain components, thereby exacerbating ROS generation. This metabolic insult, compounded by impaired iron metabolism, destabilizes the delicate redox equilibrium within cancer cells. The consequential depletion of GPX4 and xCT disables glutathione-dependent antioxidant systems, enabling unchecked lipid peroxide accumulation that culminates in ferroptotic death.

This research reframes the traditional view of autophagy and ferroptosis as independent processes, revealing a synergistic relationship that can be leveraged therapeutically. The dual impact of JS-K on cancer cell metabolism and survival pathways not only enhances ferroptosis but also impairs the autophagic recycling that would otherwise mitigate cellular damage—a double hit exploiting tumor vulnerabilities.

From a translational perspective, these findings offer a blueprint for the rational development of ferroptosis-based therapeutics in bladder cancer, a malignancy with few effective options beyond frontline chemotherapy. The identification of LC3B as both a mechanistic driver and biomarker enables potential patient stratification, potentially guiding personalized interventions where JS-K or similar agents might yield maximal efficacy.

Beyond direct tumor cell killing, modulation of the autophagy–ferroptosis interface may also influence the tumor immune microenvironment. Preliminary transcriptomic insights suggest that alterations in ferroptotic signaling could reshape immune cell infiltration and activation, opening avenues for combinatorial strategies incorporating immunotherapy.

Although JS-K remains at the experimental stage, its multifaceted mechanism—combining oxidative stress amplification, disruption of iron homeostasis, and suppression of antioxidant defenses—presents a compelling case for further pharmacokinetic and toxicological evaluations. Such efforts will be critical to clarify safety, dosing parameters, and therapeutic windows, paving the way for early-phase clinical trials.

Ultimately, this study propels the field toward new horizons where inducing autophagy-dependent ferroptosis could overcome resistance mechanisms that stymie conventional treatments. By illuminating this previously underappreciated axis in bladder cancer biology, the work not only offers hope for improved outcomes but also enriches the conceptual framework for future cancer drug discovery.

As the oncology community continues to grapple with lethal and refractory tumors, innovations such as JS-K-induced ferroptosis represent a paradigm shift. They underscore the necessity of targeting fundamental metabolic and survival processes, exploiting the intrinsic liabilities of cancer cells, and embracing integrated multimodal research strategies that bridge bench to bedside.

Subject of Research:
Not applicable

Article Title:
JS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study

News Publication Date:
25-Apr-2026

References:
DOI: 10.1093/pcmedi/pbag012

Image Credits:
Precision Clinical Medicine

Keywords:
Bladder cancer, ferroptosis, autophagy, JS-K, nitric oxide prodrug, iron metabolism, oxidative stress, LC3B, GPX4, xCT, tumor microenvironment, targeted therapy

Head and neck squamous cell carcinoma (HNSCC) arises from the epithelial cells lining critical regions such as the mouth, throat, and nasal cavity. The malignancy is notoriously difficult to eradicate due to its high propensity for recurrence and resistance to standard therapies like chemotherapy and radiation. These conventional treatments, while sometimes effective, often cause debilitating side effects by damaging healthy cells indiscriminately, underscoring the urgent need for more targeted and less toxic options.

The team’s approach hinges on manipulating a fat molecule called ceramide, which plays essential roles in cell health and death signaling. Ceramides, particularly the subtype C18-ceramide, are found in reduced levels in many head and neck cancers, contributing to their unchecked proliferation. LCL768 is a synthetic analog of ceramide designed to increase C18-ceramide specifically inside the mitochondria of tumor cells. This targeted accumulation initiates mitophagy, a cellular process wherein damaged mitochondria are selectively degraded, effectively cutting off the energy supply vital for cancer cell survival.

Mitophagy, often regarded as a quality control mechanism in healthy cells, becomes a double-edged sword in cancer when forcibly activated by LCL768. As cancer cells rely heavily on mitochondrial function to fulfill their heightened energy demands, the induced mitophagy leads to the systematic dismantling of these energy-producing organelles. This catastrophic energy deficit halts tumor growth and triggers cancer cell death, revealing a metabolic Achilles’ heel that the researchers expertly exploited.

Beyond inducing mitophagy, LCL768 delivers a potent metabolic blow by disrupting the tricarboxylic acid (TCA) cycle, a core component of cellular respiration. The pharmaceutical compound achieves this by depleting fumarate — a key metabolite that fuels energy production within mitochondria. This dual-action mechanism, combining ceramide-mediated mitophagy and fumarate depletion, creates a two-pronged metabolic assault that amplifies the drug’s efficacy and specificity against malignant cells.

The preclinical evaluation of LCL768 involved rigorous testing in mouse models bearing human-derived tumors and in vitro tumor cultures established from patient tissues. The researchers observed a consistent and marked elevation of mitochondrial C18-ceramide following treatment. Correspondingly, the treated tumors exhibited biochemical and structural signs of mitophagy and energy collapse, accompanied by a significant retardation in tumor progression. Crucially, supplementing fumarate to these cancer cells rescued them from LCL768’s effects, reaffirming fumarate’s essential role in cancer metabolism and the drug’s targeted action.

One of the most compelling aspects of this research is the selective toxicity of LCL768. Unlike traditional chemotherapeutics, which often harm both tumor and healthy tissues, LCL768 appeared to spare normal cells in experimental models. This specificity likely stems from the differential reliance on mitochondrial ceramide pathways and fumarate metabolism between cancerous and healthy cells. Healthy cells, less dependent on these pathways, remain largely unaffected, which could translate to reduced side effects in clinical settings.

Dr. Besim Ogretmen, the study’s lead investigator and associate director of Basic Science at MUSC Hollings Cancer Center, expressed optimism about the broader implications of this discovery. “By dismantling the internal energy infrastructure of cancer cells, we’re not only halting their growth but effectively targeting their survival strategy,” he explained. This approach could potentially extend beyond head and neck cancers to other tumor types exhibiting similar metabolic dependencies and reduced ceramide levels.

The discovery also dovetails with the growing appreciation in oncology for therapies that target cancer metabolism and stress-response systems. As tumor cells adapt to hostile environments and evade programmed cell death mechanisms, exploiting their unique metabolic frailties offers a promising route to overcome drug resistance. The innovative use of ceramide analogs like LCL768 exemplifies this strategy, marrying lipid biology with metabolic intervention to yield a potent anti-cancer weapon.

While the findings are currently confined to the preclinical stage, the research team is fervently working to transition LCL768 into clinical trials. Such trials will be critical to evaluate the safety, efficacy, and optimal delivery methods of this novel compound in human patients. The hope is that LCL768 or similar drugs may soon provide new therapeutic options for patients who face limited choices due to resistance or toxicity associated with existing treatments.

This study also features a noteworthy collaboration crossing multiple disciplines, highlighting the vital role of integrated research in tackling complex diseases like cancer. The involvement of specialists in lipidomics, molecular biology, pharmacology, and clinical oncology facilitated a comprehensive understanding of the drug’s mechanisms and potential applications.

In conclusion, the development of LCL768 represents a significant leap in cancer therapeutics, introducing a method that not only targets the tumor’s genetic drivers but also its metabolic machinery. By dual targeting mitochondrial ceramide pathways and essential metabolites like fumarate, this strategy strikes at the core of cancer cell viability. If successful in clinical translation, it may herald a new class of mitochondrial-targeting anti-cancer drugs that offer improved effectiveness with fewer side effects, fundamentally shifting the landscape of cancer treatment.

Subject of Research: Human tissue samples

Article Title: Ceramide-Induced Metabolic Stress Depletes Fumarate and Drives Mitophagy to Mediate Tumor Suppression

News Publication Date: 2-Sep-2025

Web References:

• https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-24-4042/763061/Ceramide-Induced-Metabolic-Stress-Depletes
• https://hollingscancercenter.musc.edu/

References: DOI: 10.1158/0008-5472.CAN-24-4042

Image Credits: Medical University of South Carolina

Keywords: Head and neck cancer, Ceramide signaling, Immunotherapy